TABLE 1A.

Patient Characteristics by de novo class I DSA status.

Factors	De novo A/B	De novo A/B	P-value
	DSA (+) (n = 17)	DSA (−) (n = 674)
Observation period	85.7 +/– 28.4	78.5 +/– 27.6
Recipient age	46.3 +/– 15.4	16.3 +/– 15.9
Recipient M/F	14/3	437/237
Donor age	56.9 +/– 11.1	58.0 +/– 10.1
Donor M/F	2/15	240/434	0.0422
Parent/sibling/spouse/others	7/1/9/0	282/60/305/27
CSA/TAC	12/5	340/434
MMF/MZR/EVR	13/4/0	565/34/75
RIT/SPX/NONE	4/2/11	170/8/496
HLA-A+B MM	2.6 +/– 0.8	2.1 +/– 1.0	0.0446
HLA-DRB1 MM	1.2+/– 0.8	1.2 +/– 0.6
HLA-DQB1 MM	1.2 +/– 0.7	1.1 +/– 0.6
HLA-DRB1+DQB1 MM	2.4 +/– 1.5	2.4 +/– 1.2
HLA-A+B+DRB1+DQB1 MM	5.1 +/– 2.0	4.5 +/– 2.0
ABO-I/ABO-Id/C	6/11	231/443
Eplet MM (A+B)	15.7 +/– 5.2	11.1 +/– 6.4	0.0033
Eplet MM (DRB)	7.1 +/– 7.0	11.4 +/– 8.8	0.0426
Eplet MM (DQB)	9.8 +/– 7.2	8.3 +/– 6.5
Eplet MM (DRB+DQB)	16.9 +/– 12.6	19.7 +/– 13.3
PIRCHE score	211.9 +/– 136.7	214.0 +/– 139.7
Acute TCMR	0 (0%)	56 (8.3%)
CMV infection	2 (26.0%)	196 (29.1%)